Sep 28 close
Indivior Pharmaceuticals closed at $36.88 on 28 September 2026, +3% on the day. The price sits between the 50-day ($37.16) and 200-day ($35.73) moving averages, inside a 52-week range of $22.56 to $42.81. The GekkoIndex reads 55.4, in the Neutral zone, down 7.7 points over five sessions. Gekko Fair Value is $38.55, so the price is 4.3% below it.
The next earnings report is due on 29 October 2026, 30 days away (before open). Over the last 8 reports the company beat the earnings estimate 7 times, with an average move of 13.6% across the report. Smart-money activity over the last 90 days includes 2 open-market insider purchases. Seasonally, the next 20 trading days from this point averaged +3.2% over the last 5 years, rising in 3 of them.
3 firms rate the stock: 3 buy, 0 hold and 0 sell, with a consensus target of $49.00. A typical daily move is about 2.6%, and a typical 20-day move about 10%. On the swing-trade checklist, 3 items read supportive and 0 read as a headwind.
Generated Sep 29, 2026 from the data above.
Indivior Pharmaceuticals scores 3 supportive, 3 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive3 mixed0 headwinds
Averages disagree
Close $36.88 sits between the 50-day ($37.16) and 200-day ($35.73) averages, or the averages disagree.
See the chart55.4, Neutral
Reading 55.4 is in the Neutral zone.
See the GekkoIndex4.3% below
Price is within 5% of Gekko Fair Value (4.3% below).
See fair valueLeans bullish
Last 90 days: 2 open-market insider purchases.
See smart moneyReports in 30 days
Next report Oct 29, 2026, 30 days away — outside a typical 20-trading-day hold.
See earnings+3.2% on average
From this point in the calendar, the next 20 trading days averaged +3.2% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Indivior Pharmaceuticals closed at $36.88 on Sep 28, 2026, +61.7% over the past year, inside a 52-week range of $22.56 to $42.81.
Use the left and right arrow keys to read daily values.
Put INDV on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Indivior Pharmaceuticals develops, manufactures, and distributes buprenorphine-based medicines used in treating opioid dependence. Its lineup of prescription pharmaceuticals includes Suboxone Film, Suboxone Tablet, and Subutex Tablet, products aimed at patients managing opioid use disorder. These medicines represent the core of what the company is known for within its field of prescription treatment.
Indivior Pharmaceuticals is structured as a holding company overseeing the research, production, and distribution activities tied to these medications. It organizes its operations across distinct geographic segments, namely the United States, the United Kingdom, and a broader international market that spans other regions where its products reach patients and healthcare providers.
The company was established on September 26, 2014, and its corporate headquarters are situated in North Chesterfield, Virginia. Its shares are listed on the NASDAQ under the ticker INDV, allowing investors to trade ownership in the business through that exchange.
Indivior Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 55.4, in the Neutral zone, down 7.7 points over five sessions.
Down 7.7 points over five sessions, from the Accumulation zone.
Reading for Sep 28, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 54 | +2.6% | +7.3% | ||
| Accumulation | 186 | −0.3% | −3.1% | ||
| Neutral (current zone) | 346 | +0.9% | +5.5% | ||
| Distribution | 80 | +2.6% | +5.8% | ||
| Selling | 6 | Too few readings yet | |||
Average INDV share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Indivior Pharmaceuticals trades 4.3% below Gekko Fair Value of $38.55, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Indivior Pharmaceuticals shares are worth, recalculated every trading day.
$38.55
Gekko Fair Value, Sep 29, 2026
4.3% below fair value · About fair value
Insiders filed 2 open-market purchases in Indivior Pharmaceuticals worth $108K, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
$108Kin 2 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 27 | Anderson Woodrow D officer: Chief Accounting Officer | Purchase | $54K |
| Aug 5 | Woodrow D Anderson Chief Accounting Officer | Purchase | $54K |
From Form 4 filings, dated to when each was filed.
No trades in INDV were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Indivior Pharmaceuticals has been buying back its own shares.
From company filings.
2of the funds Gekko tracks hold INDV.
Indivior Pharmaceuticals reports on Oct 29, 2026, before the open (30 days away), and beat the EPS estimate in 7 of its last 8 reports.
Oct 29, 2026
Expected before the open, 30 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 3, 2026 | $1.15 est $0.97 | $343.0M est $306.2M | −8.8% |
| Apr 30, 2026 | $0.96 est $0.66 | $317.0M est $272.8M | +10.3% |
| Feb 26, 2026 | $0.82 est $0.65 | $358.0M est $305.6M | −2.7% |
| Oct 30, 2025 | $0.72 est $0.38 | $314.0M est $306.2M | +16.4% |
| Jul 31, 2025 | $0.51 est $0.26 | $302.0M est $255.2M | +21.0% |
| Apr 24, 2025 | $0.41 est $0.22 | $266.0M est $242.3M | +22.3% |
| Feb 20, 2025 | $0.32 est $0.32 | $299.0M est $240.1M | −22.5% |
| Oct 24, 2024 | $0.54 est $0.31 | $307.0M est $260.4M | +5.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Indivior Pharmaceuticals is $49.00, +32.9% from the last close, from 3 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 3 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 17 | Craig-Hallum | — | — |
| Aug 5 | Barclays | $43 | +16.6% |
| Aug 4 | Craig-Hallum | $53 | +43.7% |
| Aug 4 | H.C. Wainwright | $48 | +30.2% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Sep 26, Indivior Pharmaceuticals averaged +3.2% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +13.6% | 3 of 5 |
| Next 10 trading days | +6.5% | 2 of 5 |
| Next 15 trading days | +1.9% | 3 of 5 |
| Next 20 trading days | +3.2% | 3 of 5 |
| Next 30 trading days | +17.9% | 3 of 5 |
For scale, INDV’s typical 20-trading-day move in either direction is about 10%.
Indivior Pharmaceuticals’s market cap is $4.60B, with a P/E ratio of 12.8 and revenue of $1.33B over the last twelve months.
Coverage of Indivior Pharmaceuticals this week reads positive: 4 positive, 3 neutral and 1 negative headlines.
Indivior Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Indivior Pharmaceuticals’s market cap is $4.60B at the Sep 28, 2026 close of $36.88, with 118.0M shares outstanding. The shares trade on a P/E ratio of 12.8.
The consensus analyst 12-month price target for Indivior Pharmaceuticals is $49.00, +32.9% from the last close. Of the 3 firms that rated the stock in the last 90 days, 3 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Indivior Pharmaceuticals is about fair value: the Sep 28, 2026 close of $36.88 is 4.3% below Gekko Fair Value of $38.55. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Indivior Pharmaceuticals is expected to report on Oct 29, 2026, before the market opens (30 days away). Analysts expect earnings of $1.06 per share on revenue of $329.4M. Indivior Pharmaceuticals beat the earnings estimate in 7 of its last 8 reports, moving 13.6% on average across the report.
Indivior Pharmaceuticals’s 52-week high is $42.81 and its 52-week low is $22.56; it closed at $36.88 on Sep 28, 2026, +61.7% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (smart money, earnings risk and seasonality), 3 as mixed (trend, gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.